---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-001811"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:51:32.897891+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Palatin Q2 FY2024 net loss $7.8M; Vyleesi sale closed; pipeline catalysts ahead

## Summary
- Net loss of $7.8M ($0.56/share) vs net income of $2.7M ($0.25) in Q2 FY2023.
- Vyleesi net product revenue $2.0M (+98% YoY); completed asset sale to Cosette for up to $171M ($12M upfront).
- Cash $9.5M + $2.3M AR at Dec 31, 2023; added $9.2M net from Feb 2024 equity offering.
- PL9643 Phase 3 dry eye disease topline data expected Feb 2024; PL8177 UC interim analysis Q2 2024.
- Phase 2 obesity (MCR4+GLP-1) and ED (bremelanotide+PDE5i) studies to start 1H 2024.

## SEC filing metadata
- accession: 0001654954-24-001811
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495424001811/0001654954-24-001811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495424001811/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-001811
- JSON: https://secwatch.observer/filing/0001654954-24-001811.json
- Plain text: https://secwatch.observer/filing/0001654954-24-001811.txt

## Key facts
- Earnings Releases
  PALATIN TECHNOLOGIES INC reported the fiscal second quarter ended December 31, 2023 results: revenue $4.3 million.
  - Period: the fiscal second quarter ended December 31, 2023
  - Revenue: $4.3 million
  - Result: reported results
  source text: consists of gross product sales of Vyleesi, net of allowances and accruals. Vyleesi gross product sales to pharmacy distributors for the quarter ended December 31, 2023 were $4.3 million, with net product reven
  evidence_url: https://www.sec.gov/Archives/edgar/data/911216/000165495424001811/0001654954-24-001811-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.